Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study
| Autor: | Agata Ruszala, Tadeusz Wojciech Lapiński, Wiesław Kryczka, Beata Dobracka, Andrzej Horban, Marta Librant-Suska, Witold Dobracki, Dorota Kozielewicz, Ewa Janczewska, Joanna Musialik, Iwona Olszok, Jacek Wroblewski, Dorota Zarębska-Michaluk, Krzysztof Jurczyk, Wladyslaw Lojewski, M. Dudziak, Hanna Berak, Krystyna Augustyniak, Arkadiusz Pisula, Barbara Postawa-Kłosińska, Robert Flisiak |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Liver Cirrhosis
Male medicine.medical_specialty Cirrhosis Alpha interferon Interferon alpha-2 Gastroenterology Antiviral Agents Telaprevir Polyethylene Glycols Cohort Studies chemistry.chemical_compound Pharmacotherapy Liver Function Tests Internal medicine Ribavirin medicine Humans Adverse effect Drug Carriers medicine.diagnostic_test Dose-Response Relationship Drug business.industry Drug Substitution Patient Acuity virus diseases Interferon-alpha General Medicine Hepatitis C Hepatitis C Chronic Middle Aged medicine.disease Recombinant Proteins Observational Study (Strobe Compliant) Treatment Outcome chemistry Immunology Drug Therapy Combination Female Poland Drug Monitoring Liver function tests business Oligopeptides medicine.drug Research Article |
| Zdroj: | Medicine |
| ISSN: | 1536-5964 |
| Popis: | We investigated the safety, efficacy, and impact of ribavirin and peginterferon dose reduction on complete early virologic response and sustained virologic response (SVR) to triple therapy with telaprevir in treatment-experienced patients with advanced liver fibrosis. Treatment was initiated for 211 patients who failed treatment with peginterferon and ribavirin, with bridging fibrosis (F3, n = 68) or cirrhosis (F4, n = 143), including 103 (49%) null-responders (NR), 30 (14%) partial responders (PR), and 78 (37%) relapsers (REL). Impaired liver function (ILF) platelets 60% of the total ribavirin dose (23% vs 44%, respectively) or 80% of the total ribavirin dose (33% vs 48%, respectively). A significant SVR24 decrease was noted subsequent to a total peginterferon dose reduction, both when comparing patients who received 60% of the total dose (NR: 0% vs 44%; REL: 33% vs 68%) and patients who received 80% of the total dose (NR: 17% vs 50%; REL: 46% vs 71%). Serious adverse events were observed in 31 patients (15%). Deaths occurred in 4 patients. All of the deceased subjects were cirrhotic members of the ILF (baseline serum albumin level |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|